Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) was the recipient of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 118,989 shares, a drop of 47.0% from the July 30th total of 224,453 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 157,426 shares, the short-interest ratio is currently 0.8 days.
Analyst Upgrades and Downgrades
Separately, Kepler Capital Markets upgraded Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.
View Our Latest Analysis on CLPBY
Coloplast A/S Price Performance
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last released its quarterly earnings results on Tuesday, August 18th. The company reported $0.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.10. Coloplast A/S had a return on equity of 38.81% and a net margin of 9.68%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.11 billion. As a group, sell-side analysts predict that Coloplast A/S will post 0.4 earnings per share for the current year.
Coloplast A/S Company Profile
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Featured Stories
- Five stocks we like better than Coloplast A/S
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
- OneMain’s Yield Comes With a Catch
- 3 AI Infrastructure Stocks to Watch Beyond NVIDIA
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
